Voyager Q3 net loss $25.9M; advances VY-TAU01 IND, SOD1 ALS candidate selection by year-end

Voyager Therapeutics, Inc.

2023-Q3 EPS reported $1.78 revenue$159,947,000

Net loss $25.9M in Q3 2023 vs net income $17.6M in Q3 2022; collaboration revenue fell to $4.6M from $41.1M.
Cash, equivalents and marketable securities $252.9M as of Sep 30, 2023; runway expected into mid-2025.
Initiated GLP tox for anti-tau antibody VY-TAU01; IND filing expected H1 2024 for Alzheimer's disease.
SOD1 ALS gene therapy program on track for development candidate selection in 2023, IND target mid-2025.
License of TRACER capsid from Pfizer to Alexion/AstraZeneca Rare Disease assigned; terms unchanged.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Voyager Therapeutics, Inc. updated its mid-2025 guidance (reaffirmed).

Period: mid-2025
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

We expect our cash, cash equivalents, and marketable securities, along with amounts expected to be received as reimbursement for development costs under the Neurocrine collaborations and interest income, to be sufficient to meet Voyager’s planned operating expenses and capital expenditure requirements into mid-2025 .

View on SEC.gov

Browse all earnings releases →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-017753

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.